INTRESO
International Treatment Solutions (INTRESO) Group has written to the EU Commission’s Standing Committee on Biocidal Products to highlight the availability of safe, effective and environmentally sustainable alternatives to sulfuryl fluoride, ahead of a 21 June meeting which will consider a ban of the chemical for the preservation treatment of wood [PT8], and as an insecticide and acaricide for the control of insects and arachnids [PT18].
On 21 June, representatives from EU Member States will vote on a proposal to ban the use of sulfuryl fluoride, an extremely harmful synthetic greenhouse gas with a global warming potential more than 4500 times that of carbon dioxide, for these fumigation purposes. In what amounts to an effective ban, the EU is considering withdrawing approvals for the continued biocidal use of sulfuryl fluoride, due to a lack of data on the potential risks to human health posed by the chemical.
INTRESO Group produces BLUEFUME™, a highly effective and environmentally sustainable drop-in replacement for sulfuryl fluoride. BLUEFUME™ is the latest iteration of a tried and tested chemical, HCN, successfully used around the world for decades. INTRESO Group’s product is fully approved in numerous markets including in the EU, UK, Australia, New Zealand, Malaysia, Morocco and South Africa. Most recently, it has been put through rigorous testing and approval processes in Australia in 2023, with subsequent regulatory approval demonstrating impressive results against the latest standards.
Effective and economical, BLUEFUME™ breaks down into naturally occurring substances, meaning it also has a far lower environmental footprint than sulfuryl fluoride.
Besides being a Biocidal Product, sulfuryl fluoride is also a Plant Protection Product for the treatment of tree logs exported from the EU. In which case, additionally, INTRESO Group’s proprietary product, Ethanedinitrile (EDN™), is a highly effective and environmentally sustainable drop-in replacement for sulfuryl fluoride and has already been approved for the fumigation of timber and wood products in countries including Australia, New Zealand, South Korea, Malaysia, Uruguay, South Africa and Turkey. EDN was also successfully used over successive years in the Czech Republic under emergency use authorization during their recent bark beetle outbreak. This demonstrates that other major agricultural exporters have moved faster than the EU in approving alternative chemicals which adhere to stringent modern safety and environmental standards.
Commenting on the potential new restrictions on the use of sulfuryl fluoride in the EU, Kade McConville, Executive Director of INTRESO Group said:
“The claims that there is no available and highly effective alternative to sulfuryl fluoride for biocidal and plant protection use are simply not true. Our products, including EDN™ and BLUEFUME, are drop-in replacements that have been shown to be efficient under a wider set of climatic conditions than sulfuryl fluoride.
With increasing evidence as to the harms to human health and the planet resulting from sulfuryl fluoride, it is vitally important that EU decision-makers consider and understand the fact that alternative solutions are readily available for use in European fumigation, and that whilst sulfuryl fluoride is a tool, it is not the only tool in the toolbox.
Ahead of this pivotal vote, I have written to the Commission to make clear that our innovative, environmentally sustainable solutions already provide an effective alternative to sulfuryl fluoride in forward-thinking countries with some of the strictest biosecurity standards, including Australia and New Zealand.”
Background
- Fumigation is essential to protect against risks of invasive pests from international trade in raw commodities, with Europe facing unprecedented levels of bark beetle breakouts in conifer forests1.
- Sulfuryl fluoride, the most widely used fumigant in the EU, has a Global Warming Potential (GWP) more than 4500 times that of carbon dioxide.
- Use of sulfuryl fluoride is increasingly globally.
- Negotiations on the EU’s F-Gas Regulation, adopted in March 2024, resulted in new monitoring and recapture requirements and considered a total ban.
- EDNTM has a GWP over 4400x lower than sulfuryl fluoride.
- For more information on INTRESO: www.intreso.com
____________________ | |
1 |
https://foresteurope.org/bark-beetle-outbreaks-in-forests-a-pan-european-view/ |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240619174501/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom